Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Radiation and intratumoral injection turn on immune system to attack brain tumor cells

03.03.2003


Researchers at Cedars-Sinai’s Maxine Dunitz Neurosurgical Institute are working to develop a non-surgical approach to brain cancer that uses radiation and the injection of specially cultured bone marrow cells into the tumor. The combination sets in motion a local and systemic immune response to kill surviving tumor cells.



The novel approach has provided promising results in a study on rats, described in the March 3 issue of the Journal of Immunotherapy. Human trials are expected to begin within the year, according to John S. Yu, M.D., senior author of the article and co-director of the Comprehensive Brain Tumor Program at the Institute.

This therapy may prove to be an important step in the development of dendritic cell immunotherapy, which Institute neurosurgeons and scientists have been using experimentally for the past few years. Early results have shown promise for extending length of survival in patients with highly aggressive brain tumors called gliomas.


Dendritic cells, elements of the immune system, "clean up" foreign proteins and in the process identify them as invaders for the immune system’s T-cells to attack. This is a key role because several mechanisms allow glioma cells to grow and spread without being detected by the immune system.

In current dendritic cell immunotherapy, neurosurgeons must first surgically remove tumor cells from the patient’s brain and culture them with dendritic cells in the laboratory. When the resulting "vaccine" is injected under the skin, the dendritic cells recognize tumor cells as invaders, triggering an immune response. The new approach is based on recent studies showing that dendritic cells can identify dying tumor cells in the body, not just tumor cells they are exposed to in the laboratory.

"If the good results we’ve seen in the animal study are repeated when we move into human trials, we may be able offer hope even for patients who have brain tumors in locations that cannot be accessed surgically," said Keith L. Black, M.D., one of the article’s authors and director of the Maxine Dunitz Neurosurgical Institute. "Over the course of the past several years, we have been involved in a number of research findings that we think will lead to dramatic changes in the way these deadly tumors are treated. Instead of exposing the patient to harsh therapies that bring with them side effects and serious risks, we’re moving toward helping the immune system heal the body itself."

A pioneer in the use of dendritic cell immunotherapy to combat brain tumors, Dr. Black directs the medical center’s Division of Neurosurgery and the Comprehensive Brain Tumor Program, and he holds the Ruth and Lawrence Harvey Chair in Neuroscience.

In the animal study, dendritic cells taken from bone marrow and cultured were injected into gliomas that contained some tumor cells that had been exposed to radiation and others that had not. As the dendritic cells began taking up and processing pieces of dying tumor, they set off a local immune system response, enlisting T-cells to destroy the tumor.

Injected dendritic cells also moved into regional lymph nodes where they would be able to activate additional T-cells to fight metastatic cancer cells. Migration to the lymph nodes also initiated a systemic immune response, enlisting other "cytokines" against glioma cells. Furthermore, dendritic cells are associated with the secretion of Interleukin-12, a naturally occurring chemical that Institute researchers have found to be extremely effective in killing glioma cells.

This is the first study in which dendritic cells have been delivered directly into brain tumors with therapeutic success. Animals receiving the dendritic cell treatment lived considerably longer than controls. Even after having new tumors implanted later, rats that had been treated with dendritic cell immunotherapy continued to survive, an indication of the long-lasting benefits of the vaccine.

Researchers hope similar benefits – with improved success rates and less need for open surgery – will be seen when the therapy moves into human trials. Radiosurgery – which focuses radiation beams from hundreds of computer-selected angles on a tumor – kills cancer cells while minimizing damage to nearby tissues and vital structures. Rarely, however, is a tumor completely obliterated. The initiation of immunotherapy is intended to "mop up" the tumor cells that escape.


Moneeb Ehtesham, M.D., post-doctoral fellow at the Institute, is the article’s first author. The work was supported in part by grant NS02232 to Dr. Yu from the National Institutes of Health.

Cedars-Sinai Medical Center is one of the largest nonprofit academic medical centers in the Western United States. For the fifth straight two-year period, it has been named Southern California’s gold standard in health care in an independent survey. Cedars-Sinai is internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well as breakthrough in biomedical research and superlative medical education. Named one of the 100 "Most Wired" hospitals in health care in 2001, the Medical Center ranks among the top 10 non-university hospitals in the nation for its research activities.


Sandra Van | EurekAlert!
Further information:
http://www.csmc.edu/

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>